Literature DB >> 28011469

Three Pathways of Colonic Carcinogenesis in Rats.

Carlos A Rubio1.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is one of the more intensively studied human malignancies. For many years, the general view has been that the vast majority of CRCs in humans evolve from conventional (tubular or villous) adenomas via the adenoma-carcinoma pathway. More recently, serrated colorectal polyps (hyperplastic polyps, sessile serrated polyps and traditional serrated adenomas) have emerged as an alternative pathway of colorectal carcinogenesis in humans. Archival sections from early experiments in Sprague-Dawley (SD) rats injected with dimethylhydrazine (DMH) were reviewed and the histology of colonic neoplasias was re-evaluated. Out of 215 colonic neoplasias, 9% were serrated adenomas and 6% serrated carcinomas, 11% conventional adenomas, 39% highly differentiated carcinomas, 21% gut-associated lymphoid tissue (GALT) carcinomas, 13% signet-ring cell carcinomas, and 1% villous carcinomas. In a more recent review of archived sections from DMH-treated rats with colonic GALT follicles, dysplastic crypts exhibiting asymmetrical bifurcations in GALT mucosa were found in 49% and colonic GALT carcinomas in 53% of 276 DMH-treated rats. Histology of the 146 colonic GALT-carcinomas revealed highly differentiated carcinoma in 75%, signet-ring cell carcinoma in 20%, mucinous carcinomas in 3% and mixed in the remaining 2%. Highly differentiated carcinomas were seen to evolve from dysplastic crypts with asymmetric bifurcations and from adenomas and signet-ring cell carcinomas, and from non-dysplastic crypts having goblet cells with marked anisocytosis. It is apparent that DMH treatment in SD rats induced conventional adenomas, conventional carcinomas, serrated adenomas, serrated carcinomas and GALT carcinomas. The paradigm permits to monitor in detail the early histological steps that epitomize the three alternative pathways of colonic carcinogenesis in SD rats. This model might be useful for analyzing different molecular aberrations evolving during the conventional adenoma-carcinoma pathway, the serrated carcinoma pathway, and the GALT carcinoma pathway of colonic carcinogenesis, under standard laboratory conditions. Copyright
© 2017 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Colon cancer; GALT carcinoma pathway; conventional carcinoma pathway; rats; review; serrated carcinoma pathway

Mesh:

Substances:

Year:  2017        PMID: 28011469     DOI: 10.21873/anticanres.11284

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  The Impact of Environmental Light Intensity on Experimental Tumor Growth.

Authors:  Mark A Suckow; William R Wolter; Giles E Duffield
Journal:  Anticancer Res       Date:  2017-09       Impact factor: 2.480

2.  Corrupted colonic crypt fission in carcinogen-treated rats.

Authors:  Carlos A Rubio
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

3.  Design, optimization and validation of genes commonly used in expression studies on DMH/AOM rat colon carcinogenesis model.

Authors:  David Bars-Cortina; Antoni Riera-Escamilla; Gemma Gou; Carme Piñol-Felis; María-José Motilva
Journal:  PeerJ       Date:  2019-01-29       Impact factor: 2.984

4.  Efficacy of ivermectin against colon cancer induced by dimethylhydrazine in male wistar rats.

Authors:  Hamzah A Alghamdi; Mohammed Al-Zharani; Nada H Aljarba; Abdullah A Alghamdi; Abdulrahman A Alghamdi; Badr A Aldahmash; Doaa M Elnagar; Saad Alkahtani
Journal:  Saudi Pharm J       Date:  2022-06-28       Impact factor: 4.562

5.  Experimental Model of Rectal Carcinogenesis Induced by N-Methyl-N-Nitrosoguanidine in Mice with Endoscopic Evaluation.

Authors:  Vanessa Foresto Machado; Rogerio Serafim Parra; Caio Abner Leite; Stefania Bovo Minto; Thiago Mattar Cunha; Fernando de Queiroz Cunha; Sergio Britto Garcia; Marley Ribeiro Feitosa; Jose Joaquim Ribeiro da Rocha; Omar Feres
Journal:  Int J Med Sci       Date:  2020-09-10       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.